Realm Therapeutics PLC (LSE:RLM) - Share price - Overview

Stock Report

Realm Therapeutics PLC RLM

Last Price
GBX43.50

Day Change
0.00|0.00%

As of 19/10/2017
17:15:00 BST | GBX
Minimum 15 Minutes Delay.

Last Close43.50p
Day Range42.50 - 45.00
Mkt Cap50.70Mil
52-Wk Range25.11 - 45.00
Yield %0.00
ISINGB00B3XBCR18
Volume445,154
P/E-4.03
P/S33.98
P/CF-5.96

Share Price

Total Returns 19/10/2017

 Chg (%)  
More ...
Realm Therapeutics PLC47.46 
FTSE 100 TR GBP3.59
 
Financials
201420152016
More ...
Income Statement
Turnover10.430.810.64
Operating Profit-4.49-3.40-5.41
Net Profit-4.27-3.43-5.43
Reported EPS-8.52-6.55-11.11
Balance Sheet
Current Assets15.9813.7417.63
Non Current Assets4.313.070.37
Total Assets20.2916.8118.00
Current Liabilities2.073.692.59
Total Liabilities2.073.692.59
Total Equity18.2213.1215.42
Cash Flow
Operating Cash Flow-1.64-2.45-3.79
Net Change in Cash10.63-3.534.45
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-12.78-25.42--1.71---
2018-17.35-23.84--1.83---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
10/10/2017PurchaseMr. Charles Spicer29.0086,20725,000.00
10/10/2017PurchaseMr. Alex Martin29.00148,11542,953.00

Company Profile

Realm Therapeutics PLC is a biopharmaceutical company which focuses on leveraging its proprietary immunomodulatory technology to protect and improve the health of adults and children.

Sector

Biotechnology

Market Position

1113 of 1835 Companies

Index

Outlook

(22/09/2017) no outlook statement

Next Event 31/12/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-1.8020.6416.56
Div Yld (E)0.001.654.09
PEG (E)0.001.431.24
ROCE-34.0919.4510.95
Op Mrgn-818.859.43-23.43
EPS Grwth0.0022.5715.02
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Charles Spicer
Chief Executive OfficerMr. Alex Martin
Grp Fin Dir, Com Sec & Chf Opp OffcrMarella Thorell
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.